Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | $725.27B | 86.9x | 1.3 | $806.06 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.9% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | $483.88B | 36.8x | 1.09 | $110.18 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.9% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | $381.17B | 25.9x | -0.48 | $158.35 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | $356.96B | 70.3x | -3.3 | $201.68 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | $257.16B | 21.2x | 0.13 | $101.65 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | $250.74B | 22x | -6.38 | $39.01 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.2% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | $250.74B | 22x | -6.38 | $308.29 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | OTC Markets | Healthcare | Pharmaceuticals | $217.63B | 12.6x | 0.14 | $106.16 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.8% Downside | Upgrade to Pro+ | |
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | $217.55B | 12.6x | 0.14 | $109.38 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.6% Upside | Upgrade to Pro+ | |
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | $204.36B | 31.5x | 8.03 | $66.27 | -7.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | $204.36B | 31.5x | 8.03 | $131.04 | -8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | NASDAQ | Healthcare | Pharmaceuticals | $171.35B | 40.5x | -0.92 | $319.29 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | $158.10B | 37.1x | -0.62 | $27.98 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.1% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | $132.19B | 27.9x | -0.55 | $52.84 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | $113.38B | -15.7x | 0.08 | $55.95 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.8% Downside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | $112.39B | 106.6x | -1.31 | $90.22 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.2% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | $91.68B | 34.2x | 1.67 | $94.67 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.3% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | $79.17B | 32.9x | 4.74 | $175.27 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.9% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | $76.72B | 30x | 2.06 | $23.36 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | $73.86B | 22.6x | -0.39 | $17.34 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | $73.86B | 22.6x | -0.39 | $37.02 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | $72.35B | 25.3x | -1.72 | $33.48 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.9% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | $68.22B | 23.5x | -1.37 | $525.28 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.8% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | $60.37B | 37x | 0.53 | $32.28 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.1% Upside | Upgrade to Pro+ | |
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | $44.84B | 23.2x | 0.47 | $14.22 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.4% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | $44.84B | 23.2x | 0.47 | $28.60 | 5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | $43.68B | 28.4x | -9.53 | $9.77 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.4% Upside | Upgrade to Pro+ | |
UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | $37.20B | 142.1x | -5.16 | $98.59 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.2% Upside | Upgrade to Pro+ | |
Alnylam | NASDAQ | Healthcare | Pharmaceuticals | $34.26B | -101.2x | -2.93 | $265.29 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.1% Upside | Upgrade to Pro+ | |
Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | $33.42B | 33.7x | -1.83 | $31.17 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.6% Upside | Upgrade to Pro+ |